Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Cytosorbents (CTSO) over the last 14 years, with Q3 2025 value amounting to 0.38%.

  • Cytosorbents' Return on Capital Employed rose 1500.0% to 0.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.38%, marking a year-over-year increase of 1500.0%. This contributed to the annual value of 0.42% for FY2024, which is 3100.0% up from last year.
  • Latest data reveals that Cytosorbents reported Return on Capital Employed of 0.38% as of Q3 2025, which was up 1500.0% from 0.41% recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Return on Capital Employed ranged from a high of 0.14% in Q1 2021 and a low of 0.86% during Q4 2023
  • Moreover, its 5-year median value for Return on Capital Employed was 0.47% (2022), whereas its average is 0.49%.
  • In the last 5 years, Cytosorbents' Return on Capital Employed soared by 5700bps in 2021 and then crashed by -4300bps in 2022.
  • Over the past 5 years, Cytosorbents' Return on Capital Employed (Quarter) stood at 0.29% in 2021, then tumbled by -105bps to 0.59% in 2022, then plummeted by -45bps to 0.86% in 2023, then skyrocketed by 48bps to 0.44% in 2024, then increased by 14bps to 0.38% in 2025.
  • Its Return on Capital Employed stands at 0.38% for Q3 2025, versus 0.41% for Q2 2025 and 0.41% for Q1 2025.